

# **Metabolites identification of chemical constituents from the eggplant (*Solanum melongena* L.) calyx in rats by UPLC/ESI/qTOF-MS analysis and their cytotoxic activities**

Yuanyuan Song <sup>a,1</sup>, Ting Mei <sup>a,1</sup>, Yan Liu <sup>b,1</sup>, Shengnan Kong <sup>b</sup>, Jincheng Zhang <sup>a</sup>, Minzhen Xie <sup>a</sup>, Shan Ou <sup>a</sup>, Meixia Liang <sup>a</sup>, Qi Wang <sup>a,\*</sup>

## **Affiliation:**

<sup>a</sup> *Department of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University, Harbin 150081, China*

<sup>b</sup> *Key Laboratory of Chinese Materia Medica, Heilongjiang University of Chinese Medicine, Harbin 150040, China*

## **\*Correspondence:**

Qi Wang, PhD, Department of Medicinal Chemistry and Natural Medicine Chemistry, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, Heilongjiang 150081, China. Tel: 86-451-86660227, E-mail address: mydearmumu@163.com.

<sup>1</sup>. These authors contributed equally to this work.

## Table of Contents

**Fig. S1.** Base peak chromatograms of **1** in rats liver after oral administration (A), extracted ion chromatograms of **1-M2** in rat liver microsomes (B), and the standard solution of **1-M2** (C) .

**Fig. S2.** Proposed metabolic pathway for **5** in rats after oral administration.

**Fig. S3.** TIC chromatograms of metabolites of *n*-trans-p-coumaroyltyramine (**1**, a), *n*-trans-p-coumaroyloctopamine (**2**, b), *n*-trans-p-coumaroylnoradrenline (**3**, c), *n*-trans-feruloyloctopamine (**4**, d), phenylpropanoid neochlorogenic acid (**5**, e) in rat liver microsomes in vitro.

**Fig. S4.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound **1** and its metabolites in rat urine.

**Fig. S5.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound **2** and its metabolites in rat urine.

**Fig. S6.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h, i, j) of compound **3** and its metabolites in rat urine.

**Fig. S7.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound **4** and its metabolites in rat urine.

**Fig. S8.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound **5** and its metabolites in rat urine.


**Table S1.** The effects of **1-5** on cell activity of A549 (human lung adenocarcinoma

cell).


**Table S2.** The effects of **1-5** on cell activity of HepG2 (human liver cancer cell).

**Table S3.** The effects of **1-5** on cell activity of HCT116 (Human colorectal cancer cells).


**Table S4.** The effects of **1-5** on cell activity of MCF7 (Human breast cancer cells).




**Figure S1.** Base peak chromatograms of **1** in rats liver after oral administration (A), extracted ion chromatograms of **1-M2** in rat liver (B), and the standard solution of **1-M2** (C) .




**Figure S2.** Proposed metabolic pathway for **5** in rats after oral administration.



**Fig. S3.** TIC chromatograms of metabolites of *n*-trans-p-coumaroyltyramine (**1**, a), *n*-trans-p-coumaroyloctopamine (**2**, b), *n*-trans-p-coumaroylnoradrenline (**3**, c), *n*-trans-feruloyloctopamine (**4**, d), phenylpropanoid neochlorogenic acid (**5**, e) in rat liver microsomes in vitro.




**Fig. S4.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound **1** and its metabolites in rat urine.




**Fig. S5.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound **2** and its metabolites in rat urine.






**Fig. S6.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h, i, j) of compound **3** and its metabolites in rat urine.



**Fig. S7.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound 4 and its metabolites in rat urine.



**Fig. S8.** Total ion chromatograms (a) and extracted ion chromatograms (b, c, d, e, f, g, h) of compound **5** and its metabolites in rat urine.

**Table S1.** The effects of **1-5** on cell activity of A549 (human lung adenocarcinoma cell).

Group	n	Cell availability (%)		
		24h	48h	72h
Control	9	100±17.80	100±6.93	100±7.28
<b>1</b>	9	88.82±7.81	73.61±5.93***	70.39±9.65***
<b>2</b>	9	90.91±8.76	78.13±11.78**	90.00±16.00
<b>3</b>	9	88.91±6.24	85.44±10.93*	90.50±11.61
<b>4</b>	9	86.06±17.06	90.27±9.93*	94.65±9.90
<b>5</b>	9	87.26±7.94*	98.61±9.80	87.73±12.73*

**Table S2.** The effects of **1-5** on cell activity of HepG2 (human liver cancer cell).

Group	n	Cell availability (%)		
		24h	48h	72h
Control	9	100±7.99	100±7.82	100±5.15
<b>1</b>	9	153.56±42.55**	162.62±48.48**	139.48±24.10**
<b>2</b>	9	139.56±26.88**	164.83±38.21**	139.85±39.56*
<b>3</b>	9	126.63±20.89**	125.33±23.30*	114.58±9.79**
<b>4</b>	9	116.55±10.34**	102.95±14.74	108.87±6.57*
<b>5</b>	9	118.04±21.15*	84.30±8.70**	101.95±5.67

**Table S3.** The effects of **1-5** on cell activity of HCT116 (Human colorectal cancer cells).

Group	n	Cell availability (%)		
		24h	48h	72h
Control	6	100±10.24	100±14.80	100±3.34
1	6	106.94±23.84	91.26±16.12	60.63±4.64***
2	6	96.46±10.19	95.26±17.11	71.06±8.45***
3	6	87.74±12.40	104.84±6.73	80.48±6.58***
4	6	95.94±6.57	102.56±8.42	100.84±8.35
5	6	80.25±7.51*	85.13±14.86*	47.04±5.07***

**Table S4.** The effects of **1-5** on cell activity of MCF7 (Human breast cancer cells).

Group	n	Cell availability (%)		
		24h	48h	72h
Control	6	100±7.50	100±8.92	100±6.64
1	6	137.08±5.17**	96.21±17.34	50.85±9.15***
2	6	131.60±14.75**	98.17±13.74	105.30±13.11
3	6	147.71±26.95***	101.12±10.16	96.05±11.35
4	6	200.04±25.17***	99.52±6.19	96.73±6.10
5	6	46.58±8.14***	31.80±5.67***	13.50±2.78***